Moderna Surges On A Key Win For Its Merck-Partnered Cancer Vaccine In Europe
stock climbed Monday after European regulators granted its Merck (MRK)-partnered personalized cancer vaccine a key designation. X Under the prime scheme designation, the European Medicines Agency gives early feedback on test results to speed up the development and evaluation of medicines that may…#merck #keytruda #melanoma #stephenhoge #ericrubin #moderna #marketsmithcom #allisongatlin #ibdagatlin (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2023 Category: Consumer Health News Source Type: news
Five S & P 500 Stocks Near Buy Points
S&P 500 medical stocks Cardinal Health (CAH), Vertex Pharmaceuticals (VRTX), Merck (MRK), Intuitive Surgical (ISRG) and Insulet (PODD) are in focus this week. Medical stocks are coming into favor again — with companies involved in biotech, pharmaceuticals, medical products and more bouncing back.…#cardinalhealth #cah #merck #intuitivesurgical #dublin #ohio #bigthree #mck #amerisourcebergen #abc (Source: Reuters: Health)
Source: Reuters: Health - April 9, 2023 Category: Consumer Health News Source Type: news
From Lab to Living Room: mRNA Therapeutics
In recent years, advancements in biotechnology have led to the development of innovative medicines such as messenger RNA (mRNA) therapeutics: a mysterious new field of science with tremendous applications in cancer, rare disease, and infectious disease. Yet, the complex science behind these novel…#rna #andrewberg #arpagaray #moderna #merck #paulburton #phd #fda #pameladavis #svpofmedicalaffairs (Source: Reuters: Health)
Source: Reuters: Health - April 7, 2023 Category: Consumer Health News Source Type: news
Bird shots: Is vaccinating poultry the best defense against a deadly bird flu?
Lakeside, California—
Hilliker’s Ranch Fresh Eggs in this San Diego suburb has 30,000 chickens in three “cage-free,” open-air barns, where birds crowd the floor like rush-hour riders on a big city subway. “A cage-free aviary is a very interesting science experiment,” says Frank Hilliker, who runs the farm his
grandfather started
in 1942. He worries mightily about infections spreading through the massed birds. On his iPhone, he pulls up a list of the vaccines his chickens get: against Newcastle disease, infectious laryngotracheitis, coryza, colibacillosis, salmonella, infectious bronchitis, and fo...
Source: ScienceNOW - April 6, 2023 Category: Science Source Type: news
Bayer Defeats Merck in Lawsuit Over Talc Liabilities Bayer Defeats Merck in Lawsuit Over Talc Liabilities
A Delaware judge on Monday dismissed Merck ' s lawsuit seeking to hold Bayer responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck ' s consumer care business in 2014.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Bayer defeats Merck in lawsuit over talc liabilities
[1/2] Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly April 3 (Reuters) - A Delaware judge on Monday dismissed Merck & Co's (MRK.N) lawsuit seeking to hold Bayer AG (BAYGn.DE) responsible for more talc-related liabilities…#merckco #kenilworth #newjersey #andrewkelly #delaware #bayerag #baygn #merck #nathancook #bayer (Source: Reuters: Health)
Source: Reuters: Health - April 3, 2023 Category: Consumer Health News Source Type: news
FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma
On April 3, 2023, the Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 3, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Padcev (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) April 3, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2023 Category: Drugs & Pharmacology Source Type: news
Q & A: Digital health startups need to rethink their stories to raise in 2023
Bill Taranto, president of Merck Global Health Innovation Fund, discusses the current funding environment and how digital health companies can ensure investment in the year ahead. (Source: mobihealthnews)
Source: mobihealthnews - March 31, 2023 Category: Information Technology Source Type: news
Merck, J & J veteran to take top job at FogPharma, whose CEO is stepping away
Greg Verdine is stepping away from the precision medicine startup he founded in 2015. A veteran of J&J and Merck& Co. is taking over the corner office. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news
FDA Converts to Full Approval Indication for Keytruda (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
RAHWAY, N.J.--(BUSINESS WIRE) March 29, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Keytruda, Merck’s anti-PD-1... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 29, 2023 Category: Drugs & Pharmacology Source Type: news
Michael J. Fox Foundation updates imaging competition
The Michael J. Fox Foundation for Parkinson's Research has named Merck as th...Read more on AuntMinnie.comRelated Reading:
AC Immune receives grant to support a-syn PET tracer development
AC Immune show first images from alpha-synuclein PET
Anavex wins $1M grant for PET research
Michael J. Fox Foundation partners on PET tracer
Michael J. Fox Foundation launches $2M PET tracer prize (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 28, 2023 Category: Radiology Source Type: news
Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study
On the heels of its $43 billion buyout by Pfizer, Seagen is slimming its cell therapy efforts. The big biotech signed a licensing deal with Gracell Biotechnologies last week, granting the smaller partner rights to certain patents, SEC documents show. Gracell will conduct preclinical and clinical…#seagen #gracell (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2023 Category: Consumer Health News Source Type: news
Making strategic sense of pharma ’s new race for competitive advantage
Cheaper, faster R&D matters hugely of course, but it is increasingly the case that commercial success will only follow if pharma can also deliver for patients and health systems. Patients are increasingly active participants in their own care. They are becoming intolerant of high-friction, low-quality provision of care. Resource constrained health systems, meanwhile, urgently require partners able to help them do more with less. Advantage in the life sciences, then, will increasingly go to those that can develop new products, services and digital ecosystems to make the most of this new competitive landscape. When...
Source: EyeForPharma - March 16, 2023 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Pfizer ’s Latest Acquisition Strengthens the Case for PFE Stock
The gold catalyst we’ve waited for (From Stansberry Research) On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share. That makes the total enterprise value $43…#stansberryresearch #pfizerinc #pfe #seageninc #pfizer #seagen #merckco #mrk #mercks #merck (Source: Reuters: Health)
Source: Reuters: Health - March 15, 2023 Category: Consumer Health News Source Type: news
